Synonym
Zuclopenthixol acetate; EINECS 288-415-5; UNII-349S2ZHF05
IUPAC/Chemical Name
(Z)-4-(3-(2-Chloro-9H-thioxanthen-9-ylidene)propyl)piperazine-1-ethyl acetate
InChi Key
DFUPOTHAXAAUMS-ZTQBIIPRSA-N
InChi Code
InChI=1S/C20H21ClN2S.C4H8O2/c21-15-7-8-20-18(14-15)16(17-4-1-2-6-19(17)24-20)5-3-11-23-12-9-22-10-13-23;1-3-6-4(2)5/h1-2,4-8,14,22H,3,9-13H2;3H2,1-2H3/b16-5-;
SMILES Code
ClC1=CC(/C2=C\CCN3CCNCC3)=C(SC4=C2C=CC=C4)C=C1.CC(OCC)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
445.02
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
Jayakody K, Gibson RC, Kumar A, Gunadasa S.
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD000525. doi: 10.1002/14651858.CD000525.pub3.
PMID: 22513898 Free PMC article. Review.
2. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
Gibson RC, Fenton M, Coutinho ES, Campbell C.
Cochrane Database Syst Rev. 2004;(3):CD000525. doi:
3. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses.
Fenton M, Coutinho ES, Campbell C.
Cochrane Database Syst Rev. 2001;(3):CD000525. doi: 10.1002/14651858.CD000525.
PMID: 11686965 Updated. Review.
4. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses.
Fenton M, Coutinho ES, Campbell C.
Cochrane Database Syst Rev. 2000;(2):CD000525. doi: 10.1002/14651858.CD000525.
PMID: 10796549 Updated. Review.
5. Zuclopenthixol versus placebo for schizophrenia.
Lacey M, Jayaram MB.
Cochrane Database Syst Rev. 2015 Dec 1;(12):CD010598. doi:
6. Zuclopenthixol-acetate treatment in catatonic patients: the implication of iron metabolism.
Conca A, Bertsch E, Küng A, Waschgler R, Hrubos W, König P, Hansen M.
Eur Psychiatry. 2003 Feb;18(1):28-31. doi: 10.1016/s0924-9338(02)00008-1.
PMID: 12648893 Clinical Trial.
7. Economic evaluation of zuclopenthixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis.
Laurier C, Kennedy W, Lachaine J, Gariepy L, Tessier G.
Clin Ther. 1997 Mar-Apr;19(2):316-29. doi: 10.1016/s0149-2918(97)80120-8.
PMID: 9152570
8. Zuclopenthixol acetate in psychiatric emergencies: looking for evidence from clinical trials.
Coutinho E, Fenton M, Adams C, Campbell C.
Schizophr Res. 2000 Dec 15;46(2-3):111-8. doi: 10.1016/s0920-9964(99)00226-1.
PMID: 11120423
9. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis.
Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, Pedersen V, Elgen K, Brekke B, Fredslund-Andersen K, et al.
Acta Psychiatr Scand. 1993 Jan;87(1):48-58. doi: 10.1111/j.1600-0447.1993.tb03329.x.
PMID: 8093824 Clinical Trial.
10. Zuclopenthixol acetate (Clopixol Acuphase) for rapid sedation.
Malhi GS, Holloway F, Taylor D.
Int J Psychiatry Clin Pract. 1999;3(2):135-6. doi: 10.3109/13651509909024774.
PMID: 24941096
